Duvelisib, an oral dual PI3K‐δ,γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T‐cell lymphoma: Rationale for the phase 2 PRIMO trial Meeting Abstract

  

Authors:	Horwitz, S. M.; Foss, F. M.; Porcu, P.; Moskowitz, A.; Mehta‐Shah, N.; Jacobsen, E.; Khodadoust, M. S.; Kim, Y. H.; Weinstock, D.; Lustgarten, S.; Baglio, M.; Youssoufian, H.; Brammer, J.
Abstract Title:	Duvelisib, an oral dual PI3K‐δ,γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T‐cell lymphoma: Rationale for the phase 2 PRIMO trial
Meeting Title:	15th International Conference on Malignant Lymphoma
Journal Title:	Hematological Oncology
Volume:	37
Issue:	Suppl. 2
Meeting Dates:	2019 Jun 18-22
Meeting Location:	Lugano, Switzerland
ISSN:	0278-0232
Publisher:	Wiley Blackwell
Date Published:	2019-06-01
Start Page:	65
End Page:	66
Language:	English
ACCESSION:	136932697
DOI:	10.1002/hon.33_2629
PROVIDER:	EBSCOhost
PROVIDER:	cin20
PUBMED:	31187525
DOI/URL:	http://search.ebscohost.com/login.aspx?direct=true&db=cin20&AN=136932697&site=ehost-live
Notes:	Meeting abstract: O33 -- Source: cin20

https://synapse.mskcc.org/synapse/works/has_related_data_chk/147972